Pharmacology
Four classes of medications have been discovered to be efficient in the treatment of panic disorder: selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), benzodiazepines, and monoamine oxidase inhibitors (MAOIs). As these medications are of approximately equal effectiveness, treatment choices ought to be based on negative impacts, the client’s preferences, and other aspects of the scientific scenario.
Regardless of negative effects associated with sexual function, SSRIs are usually felt to provide the best balance between effectiveness and adverse effects. TCAs are associated with a greater threat since of cardiovascular and anticholinergic side effects. Benzodiazepines are handy in quick control of signs but are potentially addictive. MAOIs, since of the risk of hypertensive crises, are usually booked for patients unresponsive to other representatives and treatments.
On SSRIs patients may experience an initial feeling of increased stress and anxiety, jitteriness, shakiness, and agitation. Therefore, it is advised that patients begin on a lower dosage of medication than is generally used for depression. Reaction regularly does not happen for at least 4 weeks. Similar to other medication, the standard keeps in mind that the optimal period on SSRIs is not understood. When the medication is ceased, the taper ought to occur over several weeks.
Negative effects of TCAs include anticholinergic impacts, sleep disturbance, orthostatic hypotension, weight gain, sexual dysfunction, and cognitive disruption. These drugs must not be utilized for clients with acute narrow angle glaucoma or prostatic hypertrophy. Patients may suffer serious cardiac toxicity and fatality if they have preexisting cardiac conduction irregularities or if they overdose on tricyclics. Similar to the SSRIs, patients can have a stimulant action that consists of anxiety, agitation, and insomnia, and panic clients require to be begun on substantially lower doses than those utilized in treatment of anxiety. Just like other medications, there are few long-lasting outcome studies. Proof suggests that maintenance treatment is of value for at least a year after the patient has reacted to the medication. [25,26] The precise regression rate after stopping the medication is unidentified.
Alprazolam in the 5- to 6-mg/day variety has been found to be effective in dealing with a wide variety of signs in panic clients. Alprazolam has actually been shown to have an earlier beginning of action than imipramine. Negative effects of benzodiazepines include “sedation, fatigue, ataxia, slurred speech, memory disability, and weakness” (p 15). Although alprazolam must be avoided in clients with a history of compound abuse, there are no information showing that long-term usage regularly leads to an increased dose or abuse. Sometimes the medications may be prevented inappropriately due to fear of addiction. Evidence recommends that clients can have substantial difficulties tapering off alprazolam and might suffer from withdrawal symptoms and rebound stress and anxiety. [27] It is recommended that tapering proceed gradually, with a maximum decrease of 10% of the dose each week. Similar to other treatments, there are few information suggesting optimal length of treatment for responders. Some research studies recommend that imipramine may be a much better medication for panic over the long term. [28,29]
